Antibody-drug conjugates (ADCs) are a cutting-edge advancement in cancer therapy, combining monoclonal antibodies with highly potent cytotoxic drugs for precise, targeted treatment. This method optimizes therapeutic efficacy while minimizing systemic toxicity, making ADCs a pivotal development in oncology. As the global